Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guozhe Sun

Showing results (91-100 of 103) with videos related to

Pageof 11
Sort By:
Pharmacological Research|June 28, 2024
Programmed death of cardiomyocytes in cardiovascular disease and new therapeutic approachesKexin Cai, Haoyue Jiang, Yuanming Zou, et al.
JAMA Cardiology|June 18, 2024
Multifaceted Intensive Blood Pressure Control Model in Older and Younger Individuals With Hypertension: A Randomized Clinical TrialXiaofan Guo, Nanxiang Ouyang, Guozhe Sun, et al.
BMC Medicine|June 20, 2024
Impact of baseline cardiovascular risk on the outcomes of intensive blood pressure intervention: a post hoc analysis of the China rural hypertension control projectGuozhe Sun, Chang Wang, Ning Ye, et al.
Cell Research|July 13, 2023
α-myosin heavy chain lactylation maintains sarcomeric structure and function and alleviates the development of heart failureNaijin Zhang, Ying Zhang, Jiaqi Xu, et al.
Journal of the American College of Cardiology|July 8, 2026
Cardiovascular Health Change Patterns After Multifaceted Antihypertensive Intervention and Cardiovascular Outcomes: A Post Hoc Analysis of CRHCP TrialXiaofan Guo, Guozhe Sun, Ziyi Xie, et al.
China CDC Weekly|July 7, 2025
Hypertension Control in China: Translation from Clinical Trial to Real-World Application - Preliminary OutcomesGuozhe Sun, Hao Peng, Songyue Liu, et al.
Lancet (London, England)|March 5, 2023
Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trialJiang He, Nanxiang Ouyang, Xiaofan Guo, et al.
BMC Medicine|March 3, 2026
Cardiovascular outcomes of intensive blood pressure control in patients with and without metabolic dysfunction-associated fatty liver disease: post hoc analysis of the CRHCP trialSongyue Liu, Yangzhi Yin, Hongmei Yang, et al.
Lancet (London, England)|September 3, 2025
Benefit-harm trade-offs of intensive blood pressure control versus standard blood pressure control on cardiovascular and renal outcomes: an individual participant data analysis of randomised controlled trialsXiaofan Guo, Guozhe Sun, Yu Xu, et al.
JAMA Network Open|February 13, 2026
Intensive Blood Pressure Control and Cardiovascular Outcomes Across Cardiovascular-Kidney-Metabolic Syndrome Stages: A Post Hoc Analysis of the China Rural Hypertension Control ProjectXiaofan Guo, Shiyu Zhou, Jianjun Mu, et al.
Pageof 11

Showing results (91-100 of 103) with videos related to

Sort By:
Pageof 11
Pharmacological Research|June 28, 2024
Programmed death of cardiomyocytes in cardiovascular disease and new therapeutic approachesKexin Cai, Haoyue Jiang, Yuanming Zou, et al.
JAMA Cardiology|June 18, 2024
Multifaceted Intensive Blood Pressure Control Model in Older and Younger Individuals With Hypertension: A Randomized Clinical TrialXiaofan Guo, Nanxiang Ouyang, Guozhe Sun, et al.
BMC Medicine|June 20, 2024
Impact of baseline cardiovascular risk on the outcomes of intensive blood pressure intervention: a post hoc analysis of the China rural hypertension control projectGuozhe Sun, Chang Wang, Ning Ye, et al.
Cell Research|July 13, 2023
α-myosin heavy chain lactylation maintains sarcomeric structure and function and alleviates the development of heart failureNaijin Zhang, Ying Zhang, Jiaqi Xu, et al.
Journal of the American College of Cardiology|July 8, 2026
Cardiovascular Health Change Patterns After Multifaceted Antihypertensive Intervention and Cardiovascular Outcomes: A Post Hoc Analysis of CRHCP TrialXiaofan Guo, Guozhe Sun, Ziyi Xie, et al.
China CDC Weekly|July 7, 2025
Hypertension Control in China: Translation from Clinical Trial to Real-World Application - Preliminary OutcomesGuozhe Sun, Hao Peng, Songyue Liu, et al.
Lancet (London, England)|March 5, 2023
Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trialJiang He, Nanxiang Ouyang, Xiaofan Guo, et al.
BMC Medicine|March 3, 2026
Cardiovascular outcomes of intensive blood pressure control in patients with and without metabolic dysfunction-associated fatty liver disease: post hoc analysis of the CRHCP trialSongyue Liu, Yangzhi Yin, Hongmei Yang, et al.
Lancet (London, England)|September 3, 2025
Benefit-harm trade-offs of intensive blood pressure control versus standard blood pressure control on cardiovascular and renal outcomes: an individual participant data analysis of randomised controlled trialsXiaofan Guo, Guozhe Sun, Yu Xu, et al.
JAMA Network Open|February 13, 2026
Intensive Blood Pressure Control and Cardiovascular Outcomes Across Cardiovascular-Kidney-Metabolic Syndrome Stages: A Post Hoc Analysis of the China Rural Hypertension Control ProjectXiaofan Guo, Shiyu Zhou, Jianjun Mu, et al.
Pageof 11